these technologies and the test results they produce, the future of genetic testing is being ushered in with both the hope that its tremendous promise will be realized and concern over the accompanying cultural, professional, and regulatory challenges to be faced.


Issues to Address: Direct-to-consumer genetic tests have uncertain analytical and clinical validity, and questionable clinical utility. What exactly can one tell based on these tests? What can’t one tell? This will have implications for the testing companies’ claims. What types of genetic testing will become available over the next five to ten years? What will the future market look like?


Introduction to the Scope of the Workshop


David Korn, Vice Provost for Research, Harvard University


Drivers of Innovation: The Human Genome Project, Microarrays, the HapMap and the $1,000 Genome


Alan Guttmacher, Acting Director, National Human Genome Research Institute, National Institutes of Health




Direct-to-Consumer Genetic Testing: History and Scientific Foundation


Muin Khoury, Director, Office of Public Health Genomics, Centers for Disease Control and Prevention




Evolution of Direct-to-Consumer Genetic Testing: Present and Future Markets

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement